Xencor (XNCR) Upgraded to “Sell” by BidaskClub

Xencor (NASDAQ:XNCR) was upgraded by investment analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Thursday.

A number of other equities analysts have also recently commented on the company. Cantor Fitzgerald assumed coverage on Xencor in a report on Wednesday, November 29th. They set an “overweight” rating and a $33.00 target price for the company. Zacks Investment Research upgraded Xencor from a “sell” rating to a “hold” rating in a report on Wednesday, November 22nd. Piper Jaffray Companies restated a “buy” rating and set a $35.00 target price on shares of Xencor in a report on Sunday, November 12th. ValuEngine cut Xencor from a “hold” rating to a “sell” rating in a report on Monday, October 23rd. Finally, Canaccord Genuity set a $36.00 target price on Xencor and gave the company a “buy” rating in a report on Monday, October 23rd. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the company. Xencor presently has an average rating of “Hold” and a consensus price target of $30.80.

Shares of Xencor (NASDAQ XNCR) traded up $0.01 during trading on Thursday, reaching $22.26. The company had a trading volume of 144,848 shares, compared to its average volume of 215,764. Xencor has a 12 month low of $18.55 and a 12 month high of $28.64.

In related news, major shareholder John S. Stafford III purchased 24,653 shares of Xencor stock in a transaction on Wednesday, October 25th. The shares were bought at an average price of $20.01 per share, with a total value of $493,306.53. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder John S. Stafford III purchased 15,374 shares of Xencor stock in a transaction on Tuesday, November 28th. The stock was bought at an average cost of $19.86 per share, for a total transaction of $305,327.64. The disclosure for this purchase can be found here. Insiders acquired a total of 263,105 shares of company stock worth $5,206,858 in the last ninety days. 4.03% of the stock is owned by corporate insiders.

Hedge funds have recently bought and sold shares of the business. Great West Life Assurance Co. Can raised its position in Xencor by 158.9% in the 3rd quarter. Great West Life Assurance Co. Can now owns 6,526 shares of the biopharmaceutical company’s stock valued at $150,000 after purchasing an additional 4,005 shares in the last quarter. SG Americas Securities LLC raised its position in Xencor by 62.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,447 shares of the biopharmaceutical company’s stock valued at $178,000 after purchasing an additional 3,252 shares in the last quarter. Legal & General Group Plc raised its position in Xencor by 4.5% in the 2nd quarter. Legal & General Group Plc now owns 8,978 shares of the biopharmaceutical company’s stock valued at $189,000 after purchasing an additional 385 shares in the last quarter. Principal Financial Group Inc. acquired a new stake in Xencor in the 3rd quarter valued at about $201,000. Finally, Citadel Advisors LLC acquired a new stake in Xencor in the 2nd quarter valued at about $224,000. 77.62% of the stock is currently owned by institutional investors.

TRADEMARK VIOLATION NOTICE: This news story was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this news story on another site, it was copied illegally and reposted in violation of United States and international copyright and trademark law. The correct version of this news story can be read at https://www.dispatchtribunal.com/2017/12/08/xencor-xncr-upgraded-to-sell-by-bidaskclub.html.

About Xencor

Xencor, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. It has developed two clinical-stage product candidates, using its Immune Inhibitor Fc platform: XmAb5871, which is in two Phase II trials and is being developed for autoimmune disease, and XmAb7195, which is in a Phase I trial and is being developed for asthma and allergic diseases.

Analyst Recommendations for Xencor (NASDAQ:XNCR)

Receive News & Ratings for Xencor Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply